Day: May 12, 2023

ALS biomarker and long-term clinical data expected mid-year Neurology expert Ben Greenberg, M.D., M.H.S., joined as Head of MedicalSALT LAKE CITY, May 12, 2023 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced its first quarter 2023 financial results and provided recent operating highlights for the clinical programs in amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “Clene is approaching several important data milestones in ALS,” said Rob Etherington, President and CEO of Clene. “These include key biomarker data that may support accelerated FDA approval as well as additional long-term survival...

First quarter revenue grew 38% year over year NEWTOWN, PA, May 12, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for the quarter ended March 31, 2023. “As we continue our transition into a pure-play healthcare information company, Forian delivered another quarter of strong operational and financial performance,” stated Max Wygod, Chairman and Chief Executive Officer of Forian. Discontinued Operations As disclosed in its filings with the United States Securities and Exchange Commission (“SEC”), Forian completed the disposition of its cannabis software business on February 10, 2023. Through this transaction, and the previous dispositions in 2022 of Forian’s web design...

PALO ALTO, Calif., May 12, 2023 (GLOBE NEWSWIRE) — Mega Matrix Corp. (“MPU” or the “Company”) (NYSE American: MPU), today announced financial results for its fiscal first quarter ended March 31, 2023. Financial HighlightsThe Company had cash and cash equivalents of $8.6 million, and total liquidity (defined as cash equivalents and restricted cash, stable coins and digital assets) of approximately $11.6 million, as of March 31, 2023. Total assets were $12.1 million as of March 31, 2023. Equity attributable to MPU’s shareholders amounted to $13.0 million as of March 31, 2023.The Company closed one private placements during first quarter 2023, pursuant to which the Company raised gross proceeds of 6.6 million by issuance of 5,079,999 shares of common stock.Operational HighlightsTreasury holdings of...

MONTREAL, May 12, 2023 (GLOBE NEWSWIRE) — MONARCH MINING CORPORATION (“Monarch” or the “Corporation”) (TSX: GBAR) (OTCQB: GBARF) reported its results today for the third quarter ended March 31, 2023. Amounts are in Canadian dollars unless otherwise indicated. Summary of financial results(In dollars except per-share data) THREE MONTHS ENDEDMARCH 31 NINE MONTHS ENDEDMARCH 31  2023   2022   2023   2022  Revenues –   –   2,549,995   –  Cost of sales –   –   (17,546,397 ) –  Loss from mine operations –   –   (14,996,402 ) –  Administration expenses (1,427,754 ) (2,003,556 ) (3,655,707 ) (6,292,853 )Operating expenses –   (3,663,503 ) –   (3,663,503 )Care and maintenance expenses (789,025 ) –   (1,662,876 ) –  Exploration expenses –   (930,608 ) (207,868 ) (3,374,774 )Operating loss (2,216,779 ) (6,597,667 ) (20,522,853 ) (13,331,130 )         Finance...

Announced Planned Development Expansion of Briquilimab in Chronic Spontaneous Urticaria Presented Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR Announced Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia Strengthened the Board of Directors and Management Team with Multiple Appointments Raised $101.4 Million Net Proceeds in January 2023REDWOOD CITY, Calif., May 12, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous...

WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “The first quarter of 2023 was marked by the continued advancement of our lead clinical candidate MB-106, a CD20-targeted, autologous CAR T cell therapy to treat relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHL”) and chronic lymphocytic leukemia (“CLL”), through two parallel tracks. The first is the ongoing Phase 1/2 single-institution...

Prepared to Meet the Growing Demand for Aerial Firefighting BOZEMAN, Mont., May 12, 2023 (GLOBE NEWSWIRE) — Bridger Aerospace Group Holdings, Inc. (“Bridger” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today reported results for the first quarter ended March 31, 2023. Highlights:All aircraft including Super Scoopers and Air Attack are operational and ready to perform in the 2023 wildfire season First quarter 2023 operating expenses in line with management’s expectations Bridger’s receipt of its sixth Super Scooper in February 2023 creates world’s largest privately owned Super Scooper fleet On track to grow 2023 Adjusted EBITDA to between $37 million to $45 million“During the first quarter, we wrapped up our winter maintenance, flight training and carding as we prepare...

BOSTON, May 12, 2023 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2023, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. “HilleVax has continued to make excellent progress on our HIL-214 program, including the recent completion of enrollment of over 3,000 subjects in our NEST-IN1 clinical trial,” said Rob Hershberg, MD, PhD, Chairman and Chief Executive Officer of HilleVax. “We look forward to continuing to execute on our HIL-214 program and announcing top line safety and clinical efficacy...